how many people are on glp-1 drugs trends 2025: real-world data, patient outcomes & future therapies 5 years ahead: How GLP-1
Description
doi: 10.1007/s10620-015-3629-5 88 Stabroth-AkilDLeifeldLPftzerRMorgensternJKruisW
May your doses stay well-tolerated, your mind stay clear, and your progress stay steady.
CVOT, cardiovascular outcomes trial
As of publication, Ozempic and Mounjaro are not approved by the FDA for weight loss or weight management (though clinicians sometimes prescribe these drugs for such off-label uses)
L.MenetonP.MillerM
#GLP1 #OralGLP1 #NovoNordisk #EliLilly #Biopharma To view or add a comment, sign in For the past few years, GLP-1 receptor agonists have dominated the conversation around weight management
